Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Profit After Tax (2016 - 2025)

Editas Medicine (EDIT) has disclosed Profit After Tax for 11 consecutive years, with -$25.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Profit After Tax rose 59.58% to -$25.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$199.8 million, a 5.1% increase, with the full-year FY2024 number at -$237.1 million, down 54.74% from a year prior.
  • Profit After Tax was -$25.1 million for Q3 2025 at Editas Medicine, up from -$53.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$18.9 million in Q4 2023 to a low of -$76.1 million in Q1 2025.
  • A 5-year average of -$50.4 million and a median of -$53.2 million in 2025 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 599.83% in 2021, then skyrocketed 68.93% in 2023.
  • Editas Medicine's Profit After Tax stood at -$41.4 million in 2021, then plummeted by 46.58% to -$60.7 million in 2022, then surged by 68.93% to -$18.9 million in 2023, then tumbled by 140.52% to -$45.4 million in 2024, then surged by 44.67% to -$25.1 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Profit After Tax are -$25.1 million (Q3 2025), -$53.2 million (Q2 2025), and -$76.1 million (Q1 2025).